MARIETTA, Ga., April 24, 2017 /PRNewswire/ -- MiMedx Group, Inc.
(NASDAQ: MDXG), the leading biopharmaceutical company developing
and marketing regenerative biologics utilizing human placental
tissue allografts and patent-protected processes for multiple
sectors of healthcare, announced today Company's participation in
the European Wound Management Association ("EWMA") 2017 Conference
to be held in Amsterdam, The
Netherlands from May 3 through May 5,
2017.
The 2017 EWMA Conference is EWMA's 27th annual
conference offering high-level scientific presentations, knowledge
and best practices exchange, and presentation of the most recent
advances in wound management research and treatment. With up to
5,000 attendees, the EWMA is one of the largest and most
prestigious wound management conferences in the world.
MiMedx will sponsor a Symposium entitled, "The Dynamic
Impact of EpiFix® Dehydrated Human Amnion/Chorion Membrane
Allograft – Defining the New Standard for Bioactive
Healing" on May 4, 2017 from
16:00 to 17:00. Severin Läuchli, MD, will chair the symposium and
Matthew Garoufalis, DPM, FASPS,
FACFAOM, CWS, will be a symposium speaker. This symposium will
detail published peer-reviewed clinical data, clinical case
examples, and intriguing scientific evidence supporting the use of
EpiFix for the treatment for acute and chronic wounds.
Symposium Chair Dr. Läuchli is the Chief of Dermatologic
Surgery/Mohs Surgery and Wound Care and Assistant Professor,
Department of Dermatology at the University Hospital, Zurich, Switzerland, and the President of the
EWMA. Dr. Läuchli will present "The Swiss Experience with
EpiFix." Physician and study author, Dr. Garoufalis is also the
President of the International Federation of Podiatrists. Dr.
Garoufalis will present "Application Techniques and Therapeutic
Approached Using EpiFix Amniotic Allografts for Wound Healing and
Surgical Procedures."
Parker H. "Pete" Petit, CEO, said, "We are honored to be
associated with the EWMA and participate in their outstanding
conference. The EWMA is focused on investigating the barriers to
and possibilities of advanced therapies in the next generation of
wound management. They also have a key focus on the prevention and
management of surgical site infections. Their focus is well
aligned with our strategies and priorities, and we are proud to be
associated with the EWMA. Our significant participation at this
year's EWMA Conference is part of our ongoing strategy to expand
our presence in the international wound care markets and globally
market our dHACM allografts."
Bill Taylor, President and COO,
commented, "The EWMA conducts its activities in coordination with
various national and international organizations aimed at goals
such as increased data collection and quality of evidence,
implementation of knowledge, and development of education within
wound management. We share these goals in our pursuit of
advances in the treatment and healing of acute and chronic wounds.
We are excited to work with the EWMA in improving the delivery and
availability of advance wound care therapies internationally."
MiMedx will provide in-booth education during the following
times:
- May 3 from 10:30 to 18:00;
- May 4 from 9:00 to 16:30;
and
- May 5 from 9:00 to 14:30.
Throughout the conference, MiMedx will be located at Booth #3 C
06.
About MiMedx
MiMedx® is an integrated developer,
processor and marketer of patent protected and proprietary
regenerative and therapeutic biopharmaceutical products processed
from donated placental tissues. "Innovations in Regenerative
Medicine" is the framework behind our mission to give
physicians products and tissues to help the body heal itself.
We process the human placental tissue utilizing our proprietary
PURION® Process among other processes, to produce safe and
effective allografts. MiMedx proprietary processing methodology
employs aseptic processing techniques in addition to terminal
sterilization. MiMedx is the leading supplier of placental
tissue, having supplied over 800,000 allografts to date for
application in the Wound Care, Burn, Surgical, Orthopedic, Spine,
Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes
statements that look forward in time or that express management's
beliefs, expectations or hopes. Such statements are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements
are based on current information and belief, and are not guarantees
of future performance. Among the risks and uncertainties that
could cause actual results to differ materially from those
indicated by such forward-looking statements include the risk
factors detailed from time to time in the Company's periodic
Securities and Exchange Commission filings, including, without
limitation, its 10-K filing for the fiscal year ended December 31, 2016. By making these
forward-looking statements, the Company does not undertake to
update them in any manner except as may be required by the
Company's disclosure obligations in filings it makes with the
Securities and Exchange Commission under the federal securities
laws.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mimedx-to-present-at-the-european-wound-management-association-annual-conference-300444010.html
SOURCE MiMedx Group, Inc.